GMP syndrome Marketing Strategy.docVIP

 PAGE \* MERGEFORMAT 3 GMP syndrome Marketing Strategy According to SFDA statistics from related departments prior to July 1 through GMP-certified pharmaceutical companies in about 3100 or so, accounting for 60%. 2,000 companies, nearly 900 plant was forced to stop production. GMP has passed the enterprise products accounted for 90% of the domestic drug market share, covering all clinical drug commonly used varieties, fully meet the market demand. Industry There is a saying: ‘But GMP to die, and have a GMP is to court death! ‘In fact not to implement GMP, an administrative-type die; the implementation of the GMP, is economical to die. However, little information around, or news that a number of small and medium enterprises to give up GMP, certification climax in the July 1 after the repeated, that is, through the GMP to reduce low-level duplicated construction was originally conceived in vain! However, the small and medium sized pharmaceutical companies had passed the National GMP certification, but difficult to be market-proven, universal suffering GMP syndrome, the following author on this issue, to talk about their own thinking and its countermeasures. One of the symptoms, substantial increase in operating costs 1, raising the cost of clinical manifestations of (1), through the high cost of GMP It is understood that, GMP certification, 80 a number of rules, including drug labels, use the manual, defective drugs and other aspects of the handling of more than 200 inspection items related to software, hardware, management and many other aspects of the implementation of GMP is a complex and costly systems engineering. According to public information, only the transformation of a plant, business capital spending reached varies from several million to as many as tens of millions of level. According to China’s socio-economic Survey Research Center, in conjunction with relevant associations of the ‘Chinese Medicine Research Group competitiveness of enterprises